Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Eli Lilly and Company (NYSE:LLY)

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on May 08th, the Representative disclosed that they had bought between $1,001 and $15,000 in Eli Lilly and Company stock on April 14th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Revvity (NYSE:RVTY) on 5/1/2026.
• Sold $1,001 – $15,000 in shares of Flex (NASDAQ:FLEX) on 5/1/2026.
• Purchased $1,001 – $15,000 in shares of LPL Financial (NASDAQ:LPLA) on 5/1/2026.
• Purchased $1,001 – $15,000 in shares of FirstService (NASDAQ:FSV) on 5/1/2026.
• Sold $1,001 – $15,000 in shares of SS&C Technologies (NASDAQ:SSNC) on 5/1/2026.
• Purchased $1,001 – $15,000 in shares of Wayfair (NYSE:W) on 5/1/2026.
• Purchased $1,001 – $15,000 in shares of STERIS (NYSE:STE) on 5/1/2026.
• Purchased $1,001 – $15,000 in shares of DoorDash (NASDAQ:DASH) on 5/1/2026.
• Purchased $1,001 – $15,000 in shares of Sensata Technologies (NYSE:ST) on 5/1/2026.
• Purchased $1,001 – $15,000 in shares of Veralto (NYSE:VLTO) on 5/1/2026.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock traded up $23.12 during mid-day trading on Tuesday, reaching $990.11. The company had a trading volume of 3,033,622 shares, compared to its average volume of 3,215,416. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95. The company has a 50 day moving average of $941.13 and a 200-day moving average of $993.05. The firm has a market cap of $932.43 billion, a price-to-earnings ratio of 35.17, a PEG ratio of 1.03 and a beta of 0.48.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. During the same period in the prior year, the firm earned $3.34 EPS. The business’s revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, sell-side analysts expect that Eli Lilly and Company will post 35.8 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. Eli Lilly and Company’s dividend payout ratio is 24.58%.

Wall Street Analyst Weigh In

LLY has been the subject of a number of research reports. Zacks Research downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Friday, January 30th. Wells Fargo & Company increased their price target on shares of Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the company an “overweight” rating in a report on Thursday, February 5th. Truist Financial reaffirmed a “buy” rating on shares of Eli Lilly and Company in a report on Monday, February 23rd. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $1,285.00 price objective on shares of Eli Lilly and Company in a report on Friday, March 6th. Finally, Berenberg Bank raised their price objective on shares of Eli Lilly and Company from $950.00 to $1,050.00 and gave the stock a “hold” rating in a report on Thursday, February 19th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $1,218.33.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Late-stage SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN trials showed patients maintained most of their weight loss after switching from higher-dose injectable incretin therapy to Lilly’s new oral weight-loss pill Foundayo or to a lower dose of Zepbound, supporting the company’s long-term obesity pipeline. Article Title
• Positive Sentiment: Reuters reported that patients in a late-stage trial did not regain significant weight after switching from an injectable GLP-1 therapy to Foundayo, which could strengthen confidence in Lilly’s ability to expand beyond injections into oral obesity treatments. Article Title
• Positive Sentiment: Coverage framing Lilly as a dominant player in GLP-1s and a top momentum name may be adding to investor optimism around sustained demand for Zepbound and future obesity launches. Article Title
• Positive Sentiment: Lilly also announced another $4.5 billion investment in U.S. manufacturing capacity, signaling it is preparing for continued strong demand for its weight-loss drugs. Article Title
• Neutral Sentiment: The company’s 150th-anniversary charitable food-distribution initiative is positive for corporate image, but it is unlikely to have a direct near-term impact on earnings or the stock. Article Title
• Neutral Sentiment: Roche and Lilly’s Alzheimer’s blood-test partnership clearing a European regulatory hurdle is a longer-term catalyst, but it is not yet a major revenue driver. Article Title
• Negative Sentiment: An emerging obesity competitor, Kailera Therapeutics, was highlighted as a new IPO trying to challenge Lilly and Novo Nordisk, underscoring growing competition in the obesity market. Article Title
• Negative Sentiment: Separately, Reuters reported Lilly paused an India obesity-awareness campaign after regulatory scrutiny, which could create some near-term international marketing noise. Article Title

Hedge Funds Weigh In On Eli Lilly and Company

Hedge funds and other institutional investors have recently made changes to their positions in the business. Maryland Capital Advisors Inc. acquired a new stake in shares of Eli Lilly and Company during the 4th quarter worth about $25,000. Osbon Capital Management LLC acquired a new stake in shares of Eli Lilly and Company during the 4th quarter worth about $25,000. Vermillion & White Wealth Management Group LLC increased its position in shares of Eli Lilly and Company by 84.2% during the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock worth $27,000 after purchasing an additional 16 shares in the last quarter. Basso Capital Management L.P. acquired a new stake in shares of Eli Lilly and Company during the 4th quarter worth about $30,000. Finally, 10Elms LLP increased its position in shares of Eli Lilly and Company by 33.3% during the 3rd quarter. 10Elms LLP now owns 40 shares of the company’s stock worth $31,000 after purchasing an additional 10 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.